BIOTIE THERAPIES CORP 
By Biotie Therapies Corp. Stock Exchange Release 3 January 2014 at 8.55 a.m.
Change in the number of votes relating to Biotie Therapies Corp.'s shares
The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the option programs as follows:
| December 2013 | Total (5/2011- 12/2013) | Options outstanding | % of the total amount of shares |
| 12,561 | 8,415,365 | 5,295,758 | 1.2% |
The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program.
The conveyed shares previously held by the Company's subsidiary have not carried any voting rights. The parent company Biotie does not own any treasury shares. The conveyance does not affect the number of registered shares.
After the conveyances the changes are as follows:
| The increase of vote of the Company December 2013 | A total amount of voting rights: | The number of the Company's share held by the Group December 2013 | The total number of registered shares |
| 12,561 | 446,213,948 | 6,496,790 | 452,710,738 |
Turku, 3 January 2014
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com
DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire
